Pfizer Profit Margin Trend from 2010 to 2020

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  


Pfizer Profit Margin is increasing over the years with stable fluctuation. Profit Margin is expected to dwindle to 26.38. During the period from 2010 to 2020 Pfizer Profit Margin anual values regression line had geometric mean of 21.60 and mean square error of  113.92. Pfizer Net Income to Non Controlling Interests is expected to increase significantly based on the last few years of reporting. The past year's Net Income to Non Controlling Interests was at 29 Million. The current year Operating Income is expected to grow to about 12.4 B, whereas Cost of Revenue is expected to decline to about 9.9 B.

Search Historical Trends

Check Pfizer financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 12.1 B, Consolidated Income of 15.7 B or Cost of Revenue of 9.9 B, as well as many exotic indicators such as Interest Coverage of 9.09, Long Term Debt to Equity of 0.49 or Calculated Tax Rate of 9.52. This can be a perfect complement to check Pfizer Valuation or Volatility. It can also complement various Pfizer Technical models. Please check the analysis of Pfizer Correlation with competitors.

  Pfizer Quarterly Profit Margin

Pfizer Profit Margin Marginal Breakdown

Showing smoothed Profit Margin of Pfizer Inc with missing and latest data points interpolated. Measures the ratio between a company's Net Income Common Stock and Revenues.
ViewLast Reported 31.17 %10 Years Trend
 Profit Margin 

Pfizer Profit Margin Regression Statistics

Arithmetic Mean 23.62
Geometric Mean 21.60
Coefficient Of Variation 45.38
Mean Deviation 8.66
Median 20.79
Standard Deviation 10.72
Sample Variance 114.91
Range 30.48
R-Value 0.33
Mean Square Error 113.92
R-Squared 0.11
Significance 0.32
Slope 1.06
Total Sum of Squares 1,149

Pfizer Profit Margin Over Time

2010  12.18 
2011  14.84 
2012  24.70 
2013  42.65 
2014  18.42 
2015  14.25 
2016  13.66 
2017  40.55 
2018  20.79 
2019  31.45 
2020  26.38 

About Pfizer Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Pfizer investors use historical funamental indicators, such as Pfizer's Profit Margin, to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pfizer Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pfizer. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables8.22 B8.03 B8.72 B10.38 B
Inventories7.58 B7.51 B8.28 B7.42 B

Did you try this?

Run Portfolio Rebalancing Now


Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Currently Active Assets on Macroaxis

Sold over 300 shares of
few days ago
Traded for 8.62
Sold over 100 shares of
few days ago
Traded for 25.24
Sold over 60 shares of
few days ago
Traded for 44.08
Sold over 100 shares of
few days ago
Traded for 28.82
Sold few shares of
few days ago
Traded for 206.26
Please check the analysis of Pfizer Correlation with competitors. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page